Skip to main content

Table 1 Characteristic of malaria patients in the study population (n = 2044) from 2011 to 2016

From: A clinical tool to predict Plasmodium vivax recurrence in Malaysia

Patient characteristic n Percentage (%)
Age, years, (mean, 95% CI) (range) 28.0, 27.3–28.7 2 weeks −80 years
Gender (n) (%)
 Male 1558 76.2
 Female 486 23.8
Nationality (n) (%)
 Malaysian 1310 64.1
 Non-Malaysian 734 36.0
WHO Region (n) (%)
 Africa 1 0.1
 South-East Asia 522 25.5
 Western Pacific 1367 66.8
 Eastern Mediterranean 152 7.4
 Unknown 2 0.1
Glucose-6-phosphate-dehydrogenase (G6PD) (n) (%)
 Deficient 126 6.2
 Normal 1252 61.2
 Unknown 666 32.6
Pregnancy (n) (%), total = 486
 No 448 92.2
 Yes 38 7.8
Case locality
 Urban 366 17.9
 Rural 1090 53.5
 Unknown 588 28.7
Status of case locality (n) (%)
 Free 829 40.6
 Prone 164 8
 Problematic 1033 50.5
 Unknown 18 0.9
Disease characteristic
 Length of stay (days) (mean, 95% CI) (range) 6.1, 5.9–6.3 0–45
Previous malaria infection (n) (%)
 No 1418 69.4
 Yes 454 22.2
 Unknown 172 8.4
Presence of gametocyte during admission (n) (%)
 Positive 808 39.5
 Negative 579 28.3
 Unknown 657 32.1
Gametocyte/μL on admission (mean, 95% CI) (range) 857.4, 741–972 1–19,642
Asexual/μL on admission (mean, 95% CI) (range) 6402, 5458–7346 1–732,200
Week onset (week) (mean, 95% CI) (range) 20.53, 19–21 0–52
Severity (n) (%)
 Non-severe 1961 95.9
 Severe 55 2.7
 Unknown 28 1.4
Malaria transmission type (n) (%)
 Imported 739 36.2
 Indigenous 1195 58.5
 Introduced 47 2.3
 Relapse before 63 3.1
Treatment characteristic
 Type of antimalarial drugs (n) (%)
  CQ plus PQ 1373 67.2
  ACT plus PQ 669 32.7
  No treatment 2 0.1
Status of PQ treatment (n) (%)
  Complete 2014 98.5
  Incomplete 14 0.7
  Unknown 16 0.8
  1. G6PD Glucose-6-phosphate dehydrogenase, CQ Chloroquine, PQ Primaquine, ACT Artemisinin-based combination therapies